CSGADP was established in 2001 as a collaborative network of investigators with a focus on halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression with an emphasis on Type 1 diabetes.
Main Areas of Focus
- To engage in scientific discovery that significantly advances knowledge for the prevention and regulation of autoimmune disease
- To identify common and disease-specific mechanisms of autoimmunity that can lead to novel pathways and methods to predict autoimmune disease and prevent its development
- To connect markers of risk for autoimmune disease to alterations in immune function
- To advance our understanding of genetic and environmental risk for autoimmune disease
- To foster development of novel tools and approaches to the study of autoimmune disease risk, early pathogenesis, and onset of clinically apparent disease
- To improve visibility and foster support for understanding early events and pathways toward prevention for systemic autoimmunity
Content last reviewed on